10,000 Matching Annotations
  1. Last 7 days
    1. Representations in the J-space can be used flexibly for many tasks—for example, once “France” has lit up in Claude’s J-space, the model can recall its capital, or its national currency, or the continent it belongs to.

      In Mind

    1. d’usages de sols résidentiel (US 5)

      Je pars de l'hypothèse que les particuliers ne respectent pas cette loi, est-ce qu'il en va de même pour les entreprises privées ? Si oui, il faudrait considérer l'usage du sol 2, 3 et 5 (production secondaire, tertiaire et résidentiel) avec le risque d'inclure des espaces publics.

    2. Marais salants (MRS);

      J'avais en tête, pour une raison que j'ignore, que les marais salants étaient l'endroit où se cultive la salicorne...

    1. This salient and significant post is no longer online

      Use the internet archive to get a saved copy

      then personally archive it permanently on IPFS

    1. 💻/thinkpad/🧊/me/📓/2026/6/1/9/gotcha-ipfs.CID.versions/IPFS~drawback-by-arcana.network%40mediuml%40v0.html

      https://bafybeibwpwyj5gdhttrlmrrmtveryvacvrxeisg7gfg3vzxvi3a6vu424q.ipfs.inbrowser.link/?filename=IPFS~drawback-by-arcana.network@medium@v0.html

    1. combining global authoritative perspective

      combining global authoritative perspective with their own organisational knowledge, yielding high-value, locally contextualised answers and insights.

    1. her cash advance of PHP 200

      The cash advance should be included in the table rather than only in the solution steps, as it is a key piece of information needed to solve the problem. Presenting it in the table makes it more visible and reduces the likelihood that learners will overlook it.

    2. 20 percent as the decimal 0.20 first.

      It would also be helpful to include a brief explanation that converting a percent to a decimal simply means dividing the percent by 100 (e.g., 20 ÷ 100 = 0.20) or moving the decimal point two places to the left. This will help learners understand the conversion process rather than just memorizing the rule.

    1. Find the discount: 5 percent of 2,400 is 2,400 / 100 x 5 = 120 pesos.

      I suggest showing another way of computing the discount or presenting the formula:

      Discount Amount = Original Price × (Discount % ÷ 100)

      This alternative method can help learners better understand the process and reduce potential confusion when they are presented with the formula.

    1. P06FGerman52uk*T72PReduced2.39Pathogenic––uk47.37Severely affectedAlive

      Case#: P06. Female, German, 52 years old at the time of clinical diagnosis, Alive at the time of publication

      DiseaseAssertion: classified as "Severely affected" based on a CHAI score of 47.37%

      FamilyInfo: N/A

      CasePresentingHPOs: N/A

      CaseHPOFreeText: N/A

      CaseNotHPOs:N/A

      CaseNotHPOFreeText: N/A

      CasePreviousTesting: The percentage of transendocytosis using either CD80-GFP or CD80-mScarlet CHO cells was determined in eight LRBA-deficient patients. No difference in the percentage of transendocytosis was observed between CTLA4-variant carriers (GFP median=5.4%; mScarlet median= 49.8%) and LRBA-deficient patients (GFP median=9.9%; mScarlet median, 48.6%). However, significantly lower percentages of transendocytosis were observed in LRBA-deficient patients compared to healthy donors (HD) when using CD80-mScarlet CHO cells (median, 48.6% vs. 65.5% in HD) (Fig. ​(Fig.4e),4e). This difference was not observed with CD80-GFP CHO cells (patients median of 9.9% in patients vs. 13.9% in HD). In conclusion, the CTLA4 transendocytosis method using CD80-mScarlet CHO cells enables the functional verification of LRBA deficiency, but it cannot differentiate between LRBA deficiency and CTLA4 insufficiency.

      GenotypingMethod: NGS and Sanger sequencing

      PreviouslyPublished: N/A

      Variant: NM_005214.5(CTLA4):c.214A>C (p.Thr72Pro)

      ClinVar ID: 546886

      gnomAD: not found

      SupplementalData: Yes, all data regarding the patient was found in Table1.

    2. P04Mukuk71.4A54TReduced2.04Pathogenic49.8Pathogenic[9]NANADead

      Case#: P04, male, genetic diagnosis at the age of 71.4, ethnicity: N/A, Dead at the time of article's publication

      DiseaseAssertion: N/A

      FamilyInfo: N/A

      CasePresentingHPOs: N/A

      CaseHPOFreeText: N/A

      CaseNotHPOs:N/A

      CaseNotHPOFreeText: N/A

      CasePreviousTesting: The percentage of transendocytosis using either CD80-GFP or CD80-mScarlet CHO cells was determined in eight LRBA-deficient patients. No difference in the percentage of transendocytosis was observed between CTLA4-variant carriers (GFP median=5.4%; mScarlet median= 49.8%) and LRBA-deficient patients (GFP median=9.9%; mScarlet median, 48.6%). However, significantly lower percentages of transendocytosis were observed in LRBA-deficient patients compared to healthy donors (HD) when using CD80-mScarlet CHO cells (median, 48.6% vs. 65.5% in HD) (Fig. ​(Fig.4e),4e). This difference was not observed with CD80-GFP CHO cells (patients median of 9.9% in patients vs. 13.9% in HD). In conclusion, the CTLA4 transendocytosis method using CD80-mScarlet CHO cells enables the functional verification of LRBA deficiency, but it cannot differentiate between LRBA deficiency and CTLA4 insufficiency.

      GenotypingMethod: NGS and Sanger sequencing

      PreviouslyPublished: N/A

      Variant: NM_005214.5(CTLA4):c.160G>A (p.Ala54Thr)

      ClinVar ID: 430905

      gnomAD: not found

      SupplementalData: Yes, all data regarding the patient was found in Table1.

    1. female patient

      Case#: case_Kiyota_2018, female,1 yo (onset), Japanese ancestry reported

      DiseaseAssertion: APDS + 22q13 deletion syndrome

      FamilyInfo: de novo

      CasePresentingHPOs: (HP:0001973, HP:0000969, HP:0011134, HP:0000123, HP:0000093, HP:0003073, HP:0004431, HP:0003493, HP:0020151, HP:0033604, HP:0001263, HP:0001290, HP:0000729, HP:0002463, HP:0001249, HP:0007021, HP:0012433

      ITP systemic edema mild fever lupus nephritis proteinuria hypoalbuminemia decreased complement levels antinuclear antibody double strand DNA antibody wire-loop lesions in glomeruli delayed psychmotor development hypotonia autistic features language delay intellectual disability reduced sensitivity to pain poor social functioning

      CaseHPOFreeText: positive staining for IgG, IgA, IgM, C3 and C1q and electron-dense deposits observed through renal biopsy, along with wire-loop lesions

      CaseNotHPOs: (HP:0030882, 0010783, HP:0030880) coronary aneurysm butterfly erythema Raynaud's phenomenon

      CaseNotHPOFreeText: dysmorphic features

      CasePreviousTesting: G-band karyotyping + whole genome SNP microarray revealed 22q13 deletion syndrome

      GenotypingMethod: WES

      PreviouslyPublished:

      Variant: NM_005026.3:c.1534C > T; p.(Arg512Trp)

      ClinVarID: 1347382

      CAID: CA577258

      gnomAD: v2.1.1 Grpmax 0.00007392 (4/18252 alleles) East Asian population

      SupplementalData:

    1. c.518G>A

      Case#:1/M. 1.5 y.o. (onset) and 14 y.o. (at assessment), male

      DiseaseAssertion: Patient had arthritis, neutropenia and thrombocytopenia, lymphadenopathy, and abdominal pain. The diagnosis of CTLA4 haploinsufficiency was made retrospectively in 7 patients who underwent HSCT for life-threatening, treatment-resistant immune dysregulation and in 1 patient prospectively (unclear which patients were identified retrospectively and prospectively).

      FamilyInfo: Father was noted to have Immune dysregulation, Cytopenias and Lymphoma. The patient's father was also noted to have a complex autoimmune disease and died after autologous HSCT for non-Hodgkin lymphoma.

      CasePresentingHPOs: HP:0001369 (Arthritis), HP:0001875 (Neutropenia), HP:0001873 (Thrombocytopenia), HP:0002716 (Lymphadenopathy), HP:0002027 (Abdominal pain), HP:0002720 (Decreased circulating IgA level).

      CaseHPOFreeText: Autoimmune pancytopenia, Recurrent abdominal pain, Arthritis

      This patient was offered HSCT because of ongoing autoimmunity and risk of lymphoma because his father had complex autoimmune disease and died after autologous HSCT for non-Hodgkin lymphoma.

      All 8 patients received steroids and a calcineurin inhibitor before transplant

      Five patients (including this patient) had peripheral blood HSC grafts and received cyclosporine and mycophenolate mofetil (MMF) for graft versus host disease (GvHD) prophylaxis.

      Patient had cytomegalovirus reactivation early post-HSCT and autoimmune hemolytic anemia 6 months post-HSCT, which responded to steroids; he is now off all medication.

      CaseNotHPOs: N/A

      CaseNotHPOFreeText: Patient has low levels of IgA but IgG and IgM levels appear to be within normal range. See Table I.

      CasePreviousTesting: Not found

      GenotypingMethod: Not found

      PreviouslyPublished: Yes, Schwab et al. PMID: 29729943

      Variant: c.518G>A, p.G173E

      ClinVarID: N/A

      CAID: CA350138990

      gnomAD: Not found

      SupplementalData: More information regarding Lymphocyte subsets and Immunoglobulins in Table I. Table II contains variant information and Table III contains further details about HSCT and a breakdown of each patient's transplant procedure.

      Note: No mention of whether or not the patient was tested using transendocytosis.

    1. one patient with cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) haploinsufficiency

      Case#: Buchbinder_2019_Patient 1, female, 11 y.o. (onset) 21 y.o. (report), Caucasian

      DiseaseAssertion: cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) haploinsufficiency

      FamilyInfo: "maternal history of vitiligo, hypothyroidism, a maternal grandmother with hypothyroidism, and a maternal great grandmother with multiple sclerosis." mutation was present in the mother, maternal grandmother, and absent in the father.

      CasePresentingHPOs: HP:0002113, HP:0001085, HP:0032070, HP:0000988, HP:0002027, HP:0002017, HP:0002014, HP:0001433, HP:0001973, HP:0004313, HP:0001888, HP:0001875, HP:0033608, HP:0002716, HP:0033583, HP:0002729, HP:0001945, HP:0032154, HP:0002829, HP:0032366, HP:0032296, HP:0005479, HP:0100633, HP:0004295, HP:0100279, HP:0032203, HP:0002633, HP:0030374, HP:0045080, HP:0005415, HP:0001882, HP:0002315, HP:0000505, HP:0001250, HP:0000225, HP:0001873

      (nodular pulmonary infiltrates, papilledema, leptomeningeal enhancement, recurrent rashes, abdominal pain, vomiting, diarrhea, hepatosplenomegaly, immune cytopenias, hypogammaglobulinemia, lymphopenia, neutropenia, pulmonary nodules, adenopathy, lymphocytic pleocytosis, follicular bronchiolitis, follicular lymphoid hyperplasia, fevers, aphthous ulcerations, arthralgias, presence of direct antiglobulin, elevated IgG level, decreased IgE level, chronic esophagus inflammation, gastric mucosa inflammation, colon inflammation, intramucosal lymphoid nodules in colon, vasculitis, decreased memory B cells, decreased CD3+T, decreased CD8+T, decreased WBC, headache, decreased vision, seizures, gum bleeding, thrombocytopenia)

      CaseHPOFreeText: autoantibodies were absent except for a positive direct antiglobulin test. Improvement with corticosteroids, faint oligoclonal bands documented yet absent on subsequent evaluation. brain lesions, elevated CD19+B, decreased NK,

      CaseNotHPOs: abnormal bone marrow, abnormal bronchoscopy, abnormal IgA, abnormal IgM, positive anti neuronal antibody test

      CaseNotHPOFreeText: n/a

      CasePreviousTesting: none

      GenotypingMethod: Sanger sequencing of CTLA4

      PreviouslyPublished: not reported

      Variant: heterozygous for NM_005214.5:c.151C>T

      ClinVarID: 161109

      CAID: CA173992

      gnomAD: not found

      SupplementalData: none

    2. Clinical Challenges: Identification of Patients with Novel Primary Immunodeficiency Syndromes

      PMID: 29200144

      Gene: CTLA4, PIK3CD

      HGNC: 2505,

      Disease: CTLA-4 haploinsufficiency, APDS/PASLI

      MONDO: MONDO:0014493, MONDO:0018338

      InheritancePattern: AD (haploinsufficiency), AD

      Prevalence: <1 in 1,000,000. <1 in 1,000,000

      Penetrance: The penetrance of the phenotype among carriers of pathogenic variants is incomplete, incomplete

      Note: The authors say PI3KCD throughout the article, but I believe they meant PIK3CD.

    1. 2.1 Case report

      Case#: 2-month-old boy

      DiseaseAssertion:

      FamilyInfo: One healhy brother, noncontributory

      CasePresentingHPOs: HP:0025104(Capillary malformation) HP:0004691(2-3 toe syndactyly) HP:0001520(Large for gestational age) HP:0001548(Overgrowth) HP:0033725(Thin corpus callosum) HP:0004315(Decreased circulating IgG level) HP:0002720(Decreased circulating IgA level)

      CaseHPOFreeText: At 12 months of age two ear infections occuring four weeks apart and a bilateral eye infection.

      CaseNotHPOs: HP:0012759(Neurodevelopmental abnormality) HP:0002850(Decreased circulating total IgM)

      CaseNotHPOFreeText: Segmental overgrowth was not observed. Normal newborn bloodspot and hearing screen. Ophthalmology examination is normal. No no evidence for a capillary pial vascular malformation

      CasePreviousTesting: Whole-exome sequencing and mtDNA testing

      GenotypingMethod: Exome sequencing and mtDNA testing was performed on the patient’s blood sample and cultured fibroblast from a 3 mm punch biopsy from right lower paraspinal region.

      PreviouslyPublished: No

      Variant: NM_181523.2:c.1746-2A>G p.? 9% of the proband's blood cells (74 sequencing reads) and in 25% of the cultured fibroblasts (84 sequencing reads).

      ClinVar: https://www.ncbi.nlm.nih.gov/clinvar/variation/1298995/ germline

      CAID: CA359883172

      gnomAD: Not present in gnomAD